ZF2001
CANDIDATE VACCINE AGAINST COVID-19
Zhongyianke Biotech–Liaoning Maokangyuan Biotech COVID-19 vaccine; Zhongyianke Biotech-Liaoning Maokangyuan Biotech COVID-19 vaccine; Zifivax
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.